Treatment and Outcome of Rabbits Subjected to TBI
| Treatment Group . | TBI (cGy) . | N . | Nadir (×109/L)-150 . | Survival Outcome . | Day of Death-150 . | ||
|---|---|---|---|---|---|---|---|
| Growth Factor . | Time of Injection . | Plt . | WBC . | ||||
| None | 1,200 | 4 | 8 (7-11)† | 0.13 (0.06-0.26)‡ | 0/4 | 12 (9-16) | |
| None | 1,400 | 4 | 2 (1-9)† | 0.19 (0.11-0.23)‡ | 0/4 | 8 (5-12) | |
| G-CSF | Post | 1,400 | 4 | 5 (2-222) | 0.07 (0.05-0.11) | 0/4 | 9 (5-10) |
| G-CSF | Pre | 1,400 | 4 | 7 (3-46) | 0.09 (0.07-0.14) | 1/4 | 8 (7-8) |
| FL | Pre | 1,400 | 4 | 7 (6-7) | 0.10 (0.05-0.12) | 4/4 | NA |
| FL + G-CSF | Post | 1,200 | 2 | 4.5 (4-5) | 0.28 (0.14-0.41) | 1/2 | 8 |
| FL + G-CSF | Pre | 1,200 | 2 | 37 (20-54)† | 0.92 (0.3-1.54)‡ | 2/2 | NA |
| FL + G-CSF | Pre | 1,400 | 4 | 11 (5-15)† | 0.55 (0.36-2.39)‡ | 4/4 | NA |
| Treatment Group . | TBI (cGy) . | N . | Nadir (×109/L)-150 . | Survival Outcome . | Day of Death-150 . | ||
|---|---|---|---|---|---|---|---|
| Growth Factor . | Time of Injection . | Plt . | WBC . | ||||
| None | 1,200 | 4 | 8 (7-11)† | 0.13 (0.06-0.26)‡ | 0/4 | 12 (9-16) | |
| None | 1,400 | 4 | 2 (1-9)† | 0.19 (0.11-0.23)‡ | 0/4 | 8 (5-12) | |
| G-CSF | Post | 1,400 | 4 | 5 (2-222) | 0.07 (0.05-0.11) | 0/4 | 9 (5-10) |
| G-CSF | Pre | 1,400 | 4 | 7 (3-46) | 0.09 (0.07-0.14) | 1/4 | 8 (7-8) |
| FL | Pre | 1,400 | 4 | 7 (6-7) | 0.10 (0.05-0.12) | 4/4 | NA |
| FL + G-CSF | Post | 1,200 | 2 | 4.5 (4-5) | 0.28 (0.14-0.41) | 1/2 | 8 |
| FL + G-CSF | Pre | 1,200 | 2 | 37 (20-54)† | 0.92 (0.3-1.54)‡ | 2/2 | NA |
| FL + G-CSF | Pre | 1,400 | 4 | 11 (5-15)† | 0.55 (0.36-2.39)‡ | 4/4 | NA |
Abbreviations: Plt, platelets; WBC, white blood cells; FL, Flt 3 ligand; NA, not applicable.
Median (range).
Difference in platelet counts (†) and WBC (‡) between control group animals and FI + G-CSF pretreated animals according to unpairedt-test, P = .05 and P = .02, respectively.